Re: Beat
I listened to the conference call and they are shelving for now the new indication for VMAT 2 for now. My take is their plate with the recent partnerships is so full that they don't need any more for now. If that assumption is true, a dividend would just signal that NBIX has become a leading neurology company specializing in movement disorders. With no mention of Orilissa or UF, I think they are leaving the endocrine part to Abbvie. If I read it correctly, collaboration revenue was up significantly so maybe ABBV is gaining traction. Just collect the royalty checks KG and share a little.
IMO and we all know what my O is worth.